Drug Research in the Dark: NIDA's Secret Grant Huddles Unveiled
Published Date: 3/17/2025
Notice
Summary
The National Institute on Drug Abuse is holding secret meetings in April and May 2025 to review important grant applications and contract proposals. These closed sessions protect private info and trade secrets while deciding on funding for research on drug abuse, new toxicology tools, and treatment devices. Researchers and companies applying for grants or contracts should watch these dates closely as funding decisions could impact their projects and budgets.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
NIH Review for MSI Research Grants
The National Institute on Drug Abuse will hold a closed meeting on April 3, 2025 to review grant applications for the program “Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory.” If you are a researcher who applied to this NIDA program, the review and funding decision will be made at this closed session.
SBIR Review for Postmortem Toxicology Devices
A closed Special Emphasis Panel will meet on April 10, 2025 to review contract proposals for SBIR Phase II Topic 167: development of new postmortem toxicology screening devices that are portable, rapid, accurate, affordable, and accessible. Companies that submitted SBIR Phase II proposals on Topic 167 should note this review date because funding or contracting decisions will be made then.
Review of Medications and Devices for SUD
A closed panel will meet on May 12, 2025 to review and evaluate grant applications concerning medications and devices for treatment of substance use disorders (SUD). Researchers and companies that applied for NIDA grants or contracts in this area should note this date because the panel will make evaluation and funding decisions then.
Meetings Closed to Protect Confidential Info
The notice states the meetings are closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property (such as patentable material), and personal information. If you apply for a NIDA grant or contract, information you submit may be kept confidential during these reviews.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
Previous / Next Documents
Previous: 2025-04240, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in April 2025 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for cool science projects. If you’re involved in these research areas, keep an eye on these dates—they shape who gets money to make science happen!
Next: 2025-04242, National Center for Advancing Translational Sciences; Notice of Closed Meetings.
The National Center for Advancing Translational Sciences is holding a closed virtual meeting on April 3, 2025, to review special grant applications. These meetings are private to protect secret business info and personal details. This process helps decide who gets funding to support important health research.